Exploring Motus GI Holdings, Inc. (MOTS) Investor Profile: Who’s Buying and Why?

You're looking at Motus GI Holdings, Inc. (MOTS) and asking the right question: who is still buying a stock with a market capitalization around just $1.44 thousand and a trailing 12-month net loss of -$12.87 million? Honestly, that's the core of the puzzle here. Despite the massive financial distress, including a 2024 default notice from Kreos Capital, institutional investors still hold approximately 20.1% of the shares, which is a significant block for a micro-cap medical technology company with annual sales of only about $327.00K. So, are these seasoned funds betting on a deep-value turnaround, a last-ditch play on the Pure-Vu system's potential to revolutionize colonoscopy prep, or simply chasing the extreme volatility that comes with a beta of 1.1? We need to look past the scary -$14.69 Earnings Per Share to understand the profile of the buyers-the risk-tolerant specialists-who see opportunity where others see a 97.06% year-to-date price decline. What is their endgame, and what does this ownership structure tell you about the near-term risk and the long-shot reward in this stock?

Who Invests in Motus GI Holdings, Inc. (MOTS) and Why?

You're looking at Motus GI Holdings, Inc. (MOTS) in late 2025, so let's be defintely clear: the investor profile is dominated by the reality of its financial situation. The company ceased operations and filed for Chapter 7 bankruptcy in May 2024, which means the investment thesis has shifted entirely from growth to liquidation and extreme speculation.

The investor base is now a mix of institutional holders in the process of unwinding their positions, and a significant, highly speculative retail component trading on the Over-The-Counter (OTC) Pink Market. The stock's volatility, indicated by a Beta of 1.1, which is 10% more volatile than the S&P 500, tells you this isn't a stable holding.

Key Investor Types: The Remaining Holders

The ownership structure for Motus GI Holdings, Inc. (MOTS) is a fascinating case study in a micro-cap medical technology company that ran out of runway. As of late 2025, the breakdown shows a small institutional presence relative to its peers, plus a large, fragmented retail base.

• Institutional Investors: These are the large money managers, like mutual funds and hedge funds, who held an estimated 20.1% of shares before the cessation of operations. Their current activity is less about investing and more about managing a distressed asset sale, trying to salvage any residual value from the liquidation process.
• Retail Investors: This group holds the majority of the shares. They are typically high-risk speculators drawn to the low share price and the long-shot hope of a positive outcome from the Pure-Vu System's intellectual property (IP) sale or other residual assets.
• Company Insiders: Insider ownership is extremely low, reported at just 0.3%, which is common for a company facing this level of financial distress.

Here's the quick math on the company's scale right before the collapse: the market capitalization was only about $0.27 million in mid-2024, a fraction of what a viable medtech company needs. That's a tiny pool for any serious institutional money to swim in, so the remaining float is largely retail traders. You can read more about the underlying financial health that led to this point in Breaking Down Motus GI Holdings, Inc. (MOTS) Financial Health: Key Insights for Investors.

Investment Motivations: From Growth to Scraps

The original motivation was pure growth, but that's gone. The Pure-Vu System, designed to improve colonoscopy visualization, was the core value proposition. However, the company's inability to accelerate commercial adoption led to a severe cash crunch. The most recent available revenue data, the trailing twelve months (TTM) as of Q1 2024, was only about $327K, paired with a Q1 2024 net loss of $5.1 million. No dividends were ever paid, so that's not a factor.

Today, the motivations are strictly speculative and centered on the liquidation value:

• Liquidation Play: Institutional distressed debt funds or highly sophisticated investors might hold a position betting on a favorable distribution of remaining assets after the Chapter 7 process.
• Short-Term Trading: Retail traders are often drawn to the extreme price swings of a low-float, low-priced stock on the OTC market, attempting to profit from daily volatility.
• Long-Shot Hope: Some investors hold out hope for a surprise acquisition of the Pure-Vu System's technology at a price that would return value to shareholders, though this is a long-odds bet given the bankruptcy filing.

Investment Strategies: Pure Speculation

You won't find traditional value or long-term holding strategies here anymore. The strategies employed by the remaining investors are almost entirely short-term and high-risk. This is not a place for a buy-and-hold mindset.

The typical strategies break down like this:

To be fair, the institutional investors who were in it for the long haul are now simply managing a loss. Their original strategy was a high-growth bet on the medical device market, but operational hurdles and a Notice of Default from lenders like Kreos Capital VI (Expert Fund) LP in 2024 ended that story. The current strategy for anyone buying now is essentially a lottery ticket on the remnants of a failed enterprise.

Institutional Ownership and Major Shareholders of Motus GI Holdings, Inc. (MOTS)

You're looking at Motus GI Holdings, Inc. (MOTS) and trying to figure out who the big money is-or isn't-backing the company. The direct takeaway is this: institutional ownership is exceptionally low, and the investor profile is dominated by retail holders. This is a critical signal, as the company is currently in a formal wind-down and liquidation process, which is the single most important factor driving the stock's current value of just $0.0002 per share as of November 2025.

As a seasoned analyst, I can tell you that when a stock trades on the OTC market with a market capitalization of only about $1.278K (as of November 17, 2025), traditional institutional interest is almost non-existent. Most major institutions, like BlackRock or Vanguard, have mandates that prevent them from holding stocks with such low liquidity and market value. This situation means the general public dictates the price action, not sophisticated funds.

Who Holds the Shares? The Retail Dominance

The ownership structure for Motus GI Holdings, Inc. is starkly skewed toward individual investors. Institutions collectively hold a tiny fraction of the total shares outstanding. Specifically, institutional investors account for only 4.67% of the company's shares, while the general public holds the vast majority at 95.3%. This is defintely not a typical profile for a healthy, growing public company.

The largest single institutional holder is Armistice Capital LLC. Their position, while significant in percentage terms for the institutional slice, is minimal in the grand scheme. Here's the quick math on the top institutional position based on the latest filings:

Armistice Capital LLC's holding was last reported at a value of approximately US$67.1, underscoring the stock's low price point.

Changes in Ownership: The Liquidation Factor

Institutional buying or selling is essentially frozen. The most critical change in ownership and company strategy occurred in June 2024 when the Board of Directors approved the formal liquidation and dissolution of Motus GI Holdings, Inc. This action followed a strategic review and signals the end of the operating entity. What this estimate hides is that any remaining institutional position is likely a legacy holding awaiting the final distribution, if any, to shareholders.

• No fund is accumulating shares in a company winding down.
• The last reported change for the major institutional holder was 0%.
• The company's focus shifted from growth to asset disposition.

The money is moving out, not in. You can review the company's full journey, including its mission and financial history, at Motus GI Holdings, Inc. (MOTS): History, Ownership, Mission, How It Works & Makes Money.

Impact of Institutional Investors: A Non-Factor

In a normal company, large institutional investors act as a stabilizing force, providing liquidity and oversight. In the case of Motus GI Holdings, Inc., they are a non-factor. The low institutional presence means the stock price is highly volatile and easily moved by retail sentiment or small trading volumes. The lack of institutional capital is a symptom of the company's financial distress, which included an Annual Income loss of $-12,870 K and Annual Sales of only $320 K as reported in recent periods.

The company's strategy is no longer influenced by shareholder activism from large funds; it is dictated by the legally mandated wind-down process. This means the stock price is purely a speculative bet on the final liquidation value, if any remains after all creditors are paid. You are not investing in a business; you are trading a claim on residual assets.

Next Step: Before making any investment decision, consult the company's latest SEC filings (Form 8-K or 10-Q) for the most recent updates on the liquidation trust and the estimated residual value per share.

Key Investors and Their Impact on Motus GI Holdings, Inc. (MOTS)

You're looking at Motus GI Holdings, Inc. (MOTS) investor profile to understand who is still involved and why, but honestly, you need to start with the company's status: it's no longer an operating entity. The stock is trading on the over-the-counter market (OTCPK) following its delisting from NASDAQ, and the business initiated a wind-down of operations in 2024.

The investor profile for the 2025 fiscal year is less about growth-focused buying and more about the final ownership structure following the company's financial distress. The biggest influence in 2024/2025 came not from a traditional equity investor, but from a secured lender and a large institutional holder who was left with a significant stake.

The Remaining Institutional Stake: Armistice Capital LLC

The largest notable institutional investor remaining on record is Armistice Capital LLC. As of their last reported filing in late 2024, they held a significant position, owning 4.67% of the company's shares. This translates to approximately 335,549 shares of the common stock.

In a company with a market capitalization that had collapsed to an extremely low level-around $1.438 thousand as of late 2025-a stake of this size is highly concentrated. However, their influence on company decisions is now minimal because the company is in the process of an orderly wind-down, not strategic growth. Their primary concern is likely the outcome of the remaining liquidation process, if any capital is left after secured creditors are paid.

• Know who owns the most: Armistice Capital is the key equity player left.
• Insider ownership is negligible, sitting at only about 0.34% of the stock.

The Real Influence: Secured Lender and Wind-Down

The most critical external influence on Motus GI Holdings, Inc. (MOTS) in the 2024/2025 period was not an equity investor, but its secured lender, Kreos Capital VI (Expert Fund) LP. This is a classic example of how debt holders take control when a company faces severe financial distress.

Kreos Capital VI (Expert Fund) LP issued a Notice of Default in June 2024, a move that directly impacted the company's financial flexibility and likely accelerated the decision to cease operations. Here's the quick math: when a company defaults on its loan, the lender's rights-often to the company's assets-supersede the equity holders (stock owners). This is why the board approved a plan of distribution that triggered the default, forcing the issue.

The ultimate action that defined the company's 2025 structure was the sale of its core asset, the Pure-Vu® System technology, to CONMED Corporation (NYSE: CNMD) for approximately $14 million in the first quarter of 2024 through a court-supervised process. That sale effectively ended the business, making any equity investor's influence moot. You can read more about the strategic shift that led to this outcome, which is detailed in the Mission Statement, Vision, & Core Values of Motus GI Holdings, Inc. (MOTS).

Recent Moves and Investor Action in 2025

The most significant 'recent moves' by investors and insiders were a lack of action, which speaks volumes. In the three months leading up to late 2025, company insiders had not sold or bought any shares on the open market. This zero net activity is a clear signal that the operational chapter for the company is closed.

The institutional ownership percentage, which was around 20.1% at one point, reflects positions established before the full extent of the financial crisis was realized. For a micro-cap stock, even a small amount of institutional selling can be devastating, but the primary price action driver in 2024/2025 was the wind-down itself, not trading volume. The stock's dramatic price drop-a staggering 97.06% decline year-to-date as of mid-2024-reflects the market's reaction to the cessation of operations and the bankruptcy filing.

What this estimate hides is that the current investor base is largely composed of legacy holders or speculators on the final liquidation value, not investors betting on a turnaround. The table below summarizes the key ownership structure as of the last available filings in the 2025 fiscal year environment.

The action for you, as an investor, is to recognize that this is a defunct equity position. Any remaining value is tied to the final distribution of assets, a process where secured creditors like Kreos Capital are paid first, before any equity holders see a dime. That's the cold reality of a wind-down scenario.

Market Impact and Investor Sentiment

You're looking at Motus GI Holdings, Inc. (MOTS) and trying to figure out if there's a pulse left, and honestly, the investor sentiment is deeply negative, a harsh reflection of the company's recent operational struggles. As of November 2025, the stock is trading at a micro-cap level, with a share price around $0.0002 and a market capitalization of only about $1.278K. That's not a company; it's a rounding error for a major fund. This valuation tells you the market has largely priced in the worst-case scenario, which is a significant risk of value erosion.

The core of the problem is the company's financial state. In 2023, the last full-year data we have, Motus GI Holdings, Inc. reported annual revenue of only $319,000 against a net loss of -$12.87 million. That's a massive cash burn for a company of this size. Still, a small, dedicated group of institutional investors hasn't completely abandoned ship, which is the only real signal of residual hope. They're betting on the potential of the Pure-Vu system, the company's medical device for colonoscopy preparation, to eventually Mission Statement, Vision, & Core Values of Motus GI Holdings, Inc. (MOTS).

Who's Holding: The Institutional View

The institutional ownership structure is a study in high-risk, high-reward positioning. About 20.06% of the stock is held by institutions, which is low for a typical public company but significant given the tiny market cap. This suggests conviction from a few specialized funds, not broad market acceptance. The largest known institutional shareholder is Armistice Capital LLC, which holds a notable 4.67% of the company's shares.

Here's the quick math: Armistice Capital LLC's holding of 335,549 shares represents a bet on the Pure-Vu technology's clinical value, not on near-term profitability. You have to ask yourself: are they holding out for a strategic acquisition of the technology, or a dramatic, defintely successful turnaround? Insider ownership, conversely, is extremely low at just 0.34%, which doesn't show a lot of skin in the game from the people running the show.

• Institutional Ownership: 20.06%.
• Top Shareholder: Armistice Capital LLC (4.67% stake).
• Insider Ownership: Only 0.34%.

Recent Market Reactions and Analyst Disconnect

The stock market's reaction has been brutal and swift, reflecting the company's precarious position. The most telling recent news was the announcement of board resignations and a business wind-down. This is the market's way of saying: 'The core business model is failing.' For a stock trading at $0.0002, any major negative news can cause a complete liquidity freeze, not just a small dip.

Analyst perspectives offer a stark disconnect. Some older ratings from 2022 and 2023 gave a consensus price target of $4.25, but those targets are now irrelevant given the current financial reality. Today, the consensus is either a 'hold candidate' or simply no current recommendation at all. The forecasted annual revenue for 2026 is an optimistic $53MM, but this forecast is wildly out of sync with the 2023 actual revenue of $319,000. What this estimate hides is the massive execution risk and the capital required to bridge that gap.

To be fair, the market is reacting to facts, not forecasts. The stock's volatility is high, with a beta of 1.1, meaning it's 10% more volatile than the S&P 500, which is actually lower than you might expect for a micro-cap with this much risk. The lack of a clear, recent 'Buy' recommendation from a major brokerage firm should be your clearest signal.